西妥昔单抗联合化疗治疗转移性结直肠癌的观察  

Cetuximab in combination with chemotherapy treating metastatic colorectal cancer patients

作　　者：周琴[1] 宋洁 吴克雄[1] 胡军[1] 

机构地区：[1]新疆维吾尔自治区克拉玛依市中心医院血液肿瘤科,834000 [2]新疆维吾尔自治区塔城地区民族中医院内科

出　　处：《中国医药》2011年第12期1540-1542,共3页China Medicine

摘　　要：目的观察西妥昔单抗联合化疗方案治疗转移性结直肠癌的近期疗效及不良反应。方法11例经病理组织学确诊的转移性结直肠癌患者，给予西妥昔单抗联合FOLFOX方案治疗，西妥昔单抗首次给予负荷剂量400mg／m^2，每周给予维持剂量为250mg／m^2。结果全组11例患者中，完全缓解1例，部分缓解5例，稳定2例，进展3例，有效率54．5％（6／11），疾病控制率为72．7％（8／11），中位肿瘤进展时间为8．4个月。主要不良反应为痤疮样皮疹（9例）和腹泻（6例）。5例合并肝转移患者中经治疗后1例转化为可切除病灶。患者耐受良好，无治疗相关死亡。结论西妥昔单抗联合FOLFOX方案治疗转移性结直肠癌疗效较好，不良反应多可耐受。Objective To explore the efficacy and toxicity of cetuximab plus chemotherapy contained irinotecan or oxaliplatinin the treatment of metastatic colorectal cancer. Methods Eleven patients with metastatic colorectal cancer with histologically eonfirmeddiagnosis were treated with cetuximab in combination with FOLFOX regimen. Cetuximab Was given at an initialdose of 400 mg/m^2, followed by weekly infusions of 250 mg/m^2. Results The effects could be observed in 11 patients, 1 case complete remission, 5 cases partial remission, 2 cases stabilization of disease, 3 cases progressive disease. The rate of response was 54.5% （6/11） and the disease control rate was 72.7% （ 8/11 ）. The median time of tumorprogression was 8.4 months. The major toxicities were rash （9 cases） and diarrhea（6 cases）. Conclusion Cetuximab in combination with chemotherapy is effective and well tolerated in the treatment of patients with metastatic coloreetal cancer.

关 键 词：结直肠肿瘤 西妥昔单抗 化学治疗 

分 类 号：R735.3[医药卫生—肿瘤]